NeuroBo Pharmaceuticals Inc

-1.49 (-8.97%)

NeuroBo Pharma And Dong-A ST Partner To License And Develop Dong-A's Cardio-Metabolic Therapies

Published: 09/15/2022 13:06 GMT
NeuroBo Pharmaceuticals Inc (NRBO) - Neurobo Pharmaceuticals, Inc. and Dong-a St Co. Ltd.
Announce Strategic Collaboration to License and Develop Portfolio of Dong-a's Cardio-metabolic Therapies.
Neurobo - License Agreement to Develop & Commercialize Phase Ii Clinical Stage New Chemical Entity Da-1241 for Treatment of Nash / Type 2 Diabetes.
Neurobo Pharmaceuticals Inc - Dong-a Commits $15 Million in Equity to Strategic Collaboration.
Neurobo Pharmaceuticals Inc - License Agreement to Develop and Commercialize Phase I Ready Da-1726 for Treatment of Nash / Obesity.
Neurobo Pharmaceuticals - Under Terms of License Agreement, Dong-a Will Receive an Upfront Payment of $22 Million in Series a Convertible Preferred Stock.
Neurobo Pharmaceuticals Inc - Dong-a Will Also Be Entitled to Single Digit Royalties on Net Sales of Two Assets.